Further assessment of the prevalence of biotin supplementation and its impact on risk

Trambas, Christina; Liu, Kwong Chun; Luu, Hung N.; Louey, Warren; Lynch, Christopher J.; Sikaris, Kenneth A

doi:10.1016/j.clinbiochem.2019.01.004

Cited by 17 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extremely low prevalence (<0.2%) of high serum biotin (≥10 µ g/L) reported in this study is consistent with that reported by Trembas et al. in Australia (0.8%), 3 but dissimilar to that reported by Katzman et al. in the USA (7.4%).…”

Section: Discussionsupporting

confidence: 90%

“…1 The prevalence of high serum biotin concentrations (510 mg/L) in patient samples collected in emergency departments in the USA and Australia was reported as 7.4% and 0.8%, respectively. 2,3 The size of the problem in the UK, however, is unknown. Therefore, in a service evaluation, we measured serum biotin in routine patient samples to determine the potential prevalence of biotin immunoassay interference.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biotin immunoassay interference: A UK-based prevalence study

et al. 2020

View full text Add to dashboard Cite

BACKGROUND: Biotin interference in biotin-streptavidin-based immunoassays is increasingly reported due to individuals taking biotin containing supplements and patients prescribed biotin. The reported prevalence of serum biotin threshold (> 10 µg/L) for interference in Roche Diagnostics immunoassay tests is 0.8% in Australia and 7.4% in the USA. There are, however, no such data in UK populations. In a service evaluation, we therefore studied the prevalence of biotin interference in routine serum samples received in our laboratory. METHODS: Biotin was measured in 524 anonymised surplus serum samples in which at least one immunoassay test had been requested. RESULTS: The median (95% confidence intervals) for serum biotin was 0.27 µg/L (95% confidence limits: 0.07-0.93 µg/L). Serum biotin was <10 µg/L in all samples, <5 ug/L in 522 (99.6%) and <1 µg/L in 513 (98.1%) samples. In 4 samples serum biotin was >2.5 µg/L (0.8%). CONCLUSIONS: These data indicate that the probability of biotin immunoassay interference in our patient population is extremely low, with the exception of assays reporting the lowest interference thresholds (e.g. Ortho Troponin I assay; threshold >2.5 µg/L).

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Biotin immunoassay interference: A UK-based prevalence study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The magnitude of biotin interference is dependent on: (a) type of assay (design, sample volume), (b) time since last biotin intake (maximum impact at 1-3 h after ingestion), (c) biotin dose and (d) kidney function (delayed clearance in case of renal impairment). Studies quantifying biotin concentrations in the ED setting estimated at 0.4-0.5% the prevalence of patients admitted with vitamin levels >30 ng/mL [82,83]. Mumma et al [84] carried out a simulation of the potential negative clinical impact of biotin interference on hs-cTn T in a population of 850 patients with suspected AMI (prevalence 15%).…”

Section: Understanding the Impact Of Pre-analytical And Analytical Inmentioning

confidence: 99%

Laboratory-related issues in the measurement of cardiac troponins with highly sensitive assays

Krintus

Panteghini

2020

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

A number of assay-related issues can affect the performance of cardiac troponin (cTn) measurement in everyday practice. In this respect, it is vital that all information on cTn assays is known and that the performance characteristics of assays are objectively assessed and adequately described. The advent of the latest generation of more sensitive cTn assays has heralded a new wave of information about low concentrations of cTn in blood. These recent generation assays have improved analytical sensitivity and corresponding performance at low cTn concentrations when compared to their predecessors, providing a convincing goal for laboratory medicine in helping clinicians in the diagnosis of acute myocardial infarction. Crucial to the clinical utility of highly sensitive cTn assays is the laboratorians’ role in closely scrutinizing proposed assays and defining their value in relation to available evidence. Analytical, as well as pre-analytical and post-analytical, aspects must be documented. In this review, we describe what laboratory professionals should know about their cTn assay performance characteristics and the pre-analytical prerequisites for robustness to ensure optimal post-analytical reporting.

show abstract

“…There have been other publications which have examined the rate of biotin elevation. These have variously estimated the proportion exceeding 10 μg/L as 0.8% (ED population) [15] and 0.2% (routine laboratory requests) [16].…”

mentioning

confidence: 99%

“…In the original Mayo clinic publication measurement was by liquid chromatography tandem-mass spectrometry (LC-MS/MS) [14]. This technique was also used by two of the other groups documenting values above 10 μg/L [15,16]. The authors have used a research immunoassay which detects total serum biotin.…”

mentioning

confidence: 99%

Biotin interference in cardiac troponin immunoassay – where the wild things are?

Collinson

2020

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Further assessment of the prevalence of biotin supplementation and its impact on risk

Cited by 17 publications

References 10 publications

Biotin immunoassay interference: A UK-based prevalence study

Biotin immunoassay interference: A UK-based prevalence study

Laboratory-related issues in the measurement of cardiac troponins with highly sensitive assays

Biotin interference in cardiac troponin immunoassay – where the wild things are?

Contact Info

Product

Resources

About